CeMines, Inc.

Diagnostics company expands, relocates

Published in Law and Health Weekly, July 24th, 2004

CeMines, Inc., a privately held company since 2000 that is developing breakthrough, patent-pending platform technologies known as CeMines Molecular FingerPrinting focused on development of early stage diagnostics and targeted therapeutics for cancer and other diseases, announced that it has completed their relocation.

The Diagnostics & Therapeutics Research Division was moved from Cedars Sinai Medical Center, Los Angeles, to 11099 North Torrey Pines Road, Suite 260, La Jolla, California, 92037.

"Our new R&D facility will accommodate a significant increase in senior- level researchers and lab-support staff," said Toomas Neuman, chief scientific...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2004-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry